178 related articles for article (PubMed ID: 30428301)
1. Overcoming Drug Resistance through the Development of Selective Inhibitors of UDP-Glucuronosyltransferase Enzymes.
Osborne MJ; Coutinho de Oliveira L; Volpon L; Zahreddine HA; Borden KLB
J Mol Biol; 2019 Jan; 431(2):258-272. PubMed ID: 30428301
[TBL] [Abstract][Full Text] [Related]
2. Medicinal Chemistry and NMR Driven Discovery of Novel UDP-glucuronosyltransferase 1A Inhibitors That Overcome Therapeutic Resistance in Cells.
Osborne MJ; Sulekha A; Culjkovic-Kraljacic B; Gasiorek J; Ruediger E; Jolicouer E; Marinier A; Assouline S; Borden KLB
J Mol Biol; 2024 Jan; 436(2):168378. PubMed ID: 38043731
[TBL] [Abstract][Full Text] [Related]
3. Backbone assignment of the apo-form of the human C-terminal domain of UDP-glucuronosyltransferase 1A (UGT1A).
Osborne MJ; Coutinho de Oliveira L; Volpon L; Borden KLB
Biomol NMR Assign; 2018 Oct; 12(2):315-318. PubMed ID: 29934866
[TBL] [Abstract][Full Text] [Related]
4. Targeted screen for human UDP-glucuronosyltransferases inhibitors and the evaluation of potential drug-drug interactions with zafirlukast.
Oda S; Fujiwara R; Kutsuno Y; Fukami T; Itoh T; Yokoi T; Nakajima M
Drug Metab Dispos; 2015 Jun; 43(6):812-8. PubMed ID: 25834030
[TBL] [Abstract][Full Text] [Related]
5. Optimized assays for human UDP-glucuronosyltransferase (UGT) activities: altered alamethicin concentration and utility to screen for UGT inhibitors.
Walsky RL; Bauman JN; Bourcier K; Giddens G; Lapham K; Negahban A; Ryder TF; Obach RS; Hyland R; Goosen TC
Drug Metab Dispos; 2012 May; 40(5):1051-65. PubMed ID: 22357286
[TBL] [Abstract][Full Text] [Related]
6.
Sulekha A; Osborne MJ; Gasiorek J; Borden KLB
Biomol NMR Assign; 2023 Jun; 17(1):67-73. PubMed ID: 36757531
[TBL] [Abstract][Full Text] [Related]
7. Product inhibition of UDP-glucuronosyltransferase (UGT) enzymes by UDP obfuscates the inhibitory effects of UGT substrates.
Fujiwara R; Nakajima M; Yamanaka H; Katoh M; Yokoi T
Drug Metab Dispos; 2008 Feb; 36(2):361-7. PubMed ID: 17998297
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia.
Miners JO; Chau N; Rowland A; Burns K; McKinnon RA; Mackenzie PI; Tucker GT; Knights KM; Kichenadasse G
Biochem Pharmacol; 2017 Apr; 129():85-95. PubMed ID: 28065859
[TBL] [Abstract][Full Text] [Related]
9. Influence of N-terminal domain histidine and proline residues on the substrate selectivities of human UDP-glucuronosyltransferase 1A1, 1A6, 1A9, 2B7, and 2B10.
Kerdpin O; Mackenzie PI; Bowalgaha K; Finel M; Miners JO
Drug Metab Dispos; 2009 Sep; 37(9):1948-55. PubMed ID: 19487247
[TBL] [Abstract][Full Text] [Related]
10. In vitro selective inhibition of human UDP-glucuronosyltransferase (UGT) 1A4 by finasteride, and prediction of in vivo drug-drug interactions.
Lee SJ; Park JB; Kim D; Bae SH; Chin YW; Oh E; Bae SK
Toxicol Lett; 2015 Jan; 232(2):458-65. PubMed ID: 25448279
[TBL] [Abstract][Full Text] [Related]
11. Interactions between human UDP-glucuronosyltransferase (UGT) 2B7 and UGT1A enzymes.
Fujiwara R; Nakajima M; Oda S; Yamanaka H; Ikushiro S; Sakaki T; Yokoi T
J Pharm Sci; 2010 Jan; 99(1):442-54. PubMed ID: 19475557
[TBL] [Abstract][Full Text] [Related]
12. Identification of human UDP-glucuronosyltransferases involved in N-carbamoyl glucuronidation of lorcaserin.
Sadeque AJ; Usmani KA; Palamar S; Cerny MA; Chen WG
Drug Metab Dispos; 2012 Apr; 40(4):772-8. PubMed ID: 22259019
[TBL] [Abstract][Full Text] [Related]
13. Dog UDP-glucuronosyltransferase enzymes of subfamily 1A: cloning, expression, and activity.
Troberg J; Järvinen E; Muniz M; Sneitz N; Mosorin J; Hagström M; Finel M
Drug Metab Dispos; 2015 Jan; 43(1):107-18. PubMed ID: 25301937
[TBL] [Abstract][Full Text] [Related]
14. The glucuronidation of Delta4-3-Keto C19- and C21-hydroxysteroids by human liver microsomal and recombinant UDP-glucuronosyltransferases (UGTs): 6alpha- and 21-hydroxyprogesterone are selective substrates for UGT2B7.
Bowalgaha K; Elliot DJ; Mackenzie PI; Knights KM; Miners JO
Drug Metab Dispos; 2007 Mar; 35(3):363-70. PubMed ID: 17151189
[TBL] [Abstract][Full Text] [Related]
15. The inhibition study of human UDP-glucuronosyltransferases with cytochrome P450 selective substrates and inhibitors.
Liu Y; She M; Wu Z; Dai R
J Enzyme Inhib Med Chem; 2011 Jun; 26(3):386-93. PubMed ID: 20939765
[TBL] [Abstract][Full Text] [Related]
16. Molecular and functional characterization of UDP-glucuronosyltransferase 1A in cynomolgus macaques.
Uno Y; Takahira R; Murayama N; Ishii Y; Ikenaka Y; Ishizuka M; Yamazaki H; Ikushiro S
Biochem Pharmacol; 2018 Sep; 155():172-181. PubMed ID: 29944869
[TBL] [Abstract][Full Text] [Related]
17. Drug interaction study of natural steroids from herbs specifically toward human UDP-glucuronosyltransferase (UGT) 1A4 and their quantitative structure activity relationship (QSAR) analysis for prediction.
Xu M; Dong P; Tian X; Wang C; Huo X; Zhang B; Wu L; Deng S; Ma X
Pharmacol Res; 2016 Aug; 110():139-150. PubMed ID: 27208893
[TBL] [Abstract][Full Text] [Related]
18. Interpretation of the effects of protein kinase C inhibitors on human UDP-glucuronosyltransferase 1A (UGT1A) proteins in cellulo.
Abe Y; Fujiwara R; Oda S; Yokoi T; Nakajima M
Drug Metab Pharmacokinet; 2011 Jun; 26(3):256-65. PubMed ID: 21317540
[TBL] [Abstract][Full Text] [Related]
19. High-throughput screening technologies for drug glucuronidation profiling.
Trubetskoy O; Finel M; Trubetskoy V
J Pharm Pharmacol; 2008 Aug; 60(8):1061-7. PubMed ID: 18644198
[TBL] [Abstract][Full Text] [Related]
20. Natural and synthetic inhibitors of UDP-glucuronosyltransferase.
Grancharov K; Naydenova Z; Lozeva S; Golovinsky E
Pharmacol Ther; 2001 Feb; 89(2):171-86. PubMed ID: 11316519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
